morpholinoanthracycline MX2 (MX-2)

07/01/1994 - "KRN 8602 has been shown to produce less cardiotoxicity and alopecia, yet has comparable antitumor effects to ADM, and also has demonstrated an antitumor effect on ADM-resistant tumors. "
03/01/1990 - "In preclinical studies, KRN 8602 has been shown to produce less cardiotoxicity and alopecia, yet has comparable antitumor effects to adriamycin. "
01/01/1993 - "Anthracyclines including SM-5887, KRN-8602, ME-2303 under studies in Japan have shown comparable or superior antitumor activities and lower cardiac toxicities compared to doxorubicin in preclinical studies and therefore the results obtained in clinical trials are expected. "

07/01/1994 - "KRN 8602 has been shown to produce less cardiotoxicity and alopecia, yet has comparable antitumor effects to ADM, and also has demonstrated an antitumor effect on ADM-resistant tumors. "
03/01/1990 - "In preclinical studies, KRN 8602 has been shown to produce less cardiotoxicity and alopecia, yet has comparable antitumor effects to adriamycin. "

08/01/1993 - "MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial."
08/01/1993 - "We performed a preliminary phase II clinical trial of MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in patients with metastatic breast cancer who had failed to respond to previous chemotherapeutic regimens after clinical evidence of systemic disease. "

12/01/2000 - "Tumor growth was inhibited by 32.4% with DOX despite a tendency (p < 0.16) and by 59.4% with MX-2 (p < 0.001); neither of these drugs resulted in complete tumor regression. "
12/01/1991 - "[Pharmacokinetics of KRN 8602 in cancer patients]."
08/01/1989 - "MX-2 was active even against ADM-resistant cancer cells. "
05/01/1988 - "The increased life span was 40, 40, 40 (p less than 0.01), and 20% (p less than 0.05) in the animals given intravenous MX-2 of 1.5, 1.0, 0.75, and 0.375 mg/kg on day 1, 5, and 9 after tumor inoculation respectively. "
03/01/1990 - "In addition, KRN 8602 has shown antitumor effects on adriamycin-resistant tumors. "

09/01/1995 - "[Antitumor effect of KRN 8602 for malignant brain tumors using collagen gel matrix assay]."
05/01/1988 - "These results indicate that MX-2 may be a promising new antineoplastic agent for the treatment of malignant brain tumor."